Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
- Author(s):
- Howard, J.F.; Bril, V.; Burns, T.M.; Mantegazza, R.; Bilinska, M.; Szczudlik, A.; Beydoun, S.; Garrido, F.J.R.D.; Piehl, F.; Rottoli, M.; Damme, P. van; Vu, T.; Evoli, A.; Freimer, M.; Mozaffar, T.; Ward, E.S.; Dreier, T.; Ulrichts, P.; Verschueren, K.; Guglietta, A.; Haard, H. de; Leupin, N.; Verschuuren, J.J.G.M. (0000-0002-4572-1501); Claeys, K.; Diez-Tejedor, E.; Mathew, V.; Sgarzi, M.; Harvey, B.L.; Farias, J.; Frangiomore, R.; Heintzman, S.; Meel, R. de; Chopra, M.; Alboini, P.E.; Hietala, A.; Genge, A.; Efgartigimod MG Study Grp
- Published
- 2019
- Publication type
- Article / Letter to editor
- Date issued
- 2019-06-04
- Language
- English
- Is part of
- Neurology (2019), Vol. 92, no. 23, p. E2661-E2673
- hdl
- 1887/120809
- doi
- 10.1212/WNL.0000000000007600